PET/CT in therapy evaluation of patients with lung cancer

Natasha Hemicke Langer; Tine Nøhr Christensen; Seppo W Langer; Andreas Kjaer; Barbara Malene Fischer

doi:10.1586/14737140.2014.883280

PET/CT in therapy evaluation of patients with lung cancer

Natasha Hemicke Langer, Tine Nøhr Christensen, Seppo W Langer, Andreas Kjaer, Barbara Malene Fischer

5 Citationer (Scopus)

Abstract

FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

Originalsprog	Engelsk
Tidsskrift	Expert Review of Anticancer Therapy
Vol/bind	14
Udgave nummer	5
Sider (fra-til)	595-620
Antal sider	26
ISSN	1473-7140
DOI	https://doi.org/10.1586/14737140.2014.883280
Status	Udgivet - maj 2014

Emneord

Humans
Lung Neoplasms
Multimodal Imaging
Positron-Emission Tomography
Tomography, X-Ray Computed

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1586/14737140.2014.883280

Citationsformater

@article{8a17c044e6c541349b77f35862002ba5,

title = "PET/CT in therapy evaluation of patients with lung cancer",

abstract = "FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.",

keywords = "Humans, Lung Neoplasms, Multimodal Imaging, Positron-Emission Tomography, Tomography, X-Ray Computed",

author = "Langer, {Natasha Hemicke} and Christensen, {Tine N{\o}hr} and Langer, {Seppo W} and Andreas Kjaer and Fischer, {Barbara Malene}",

year = "2014",

month = may,

doi = "10.1586/14737140.2014.883280",

language = "English",

volume = "14",

pages = "595--620",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - PET/CT in therapy evaluation of patients with lung cancer

AU - Langer, Natasha Hemicke

AU - Christensen, Tine Nøhr

AU - Langer, Seppo W

AU - Kjaer, Andreas

AU - Fischer, Barbara Malene

PY - 2014/5

Y1 - 2014/5

N2 - FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

AB - FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

KW - Humans

KW - Lung Neoplasms

KW - Multimodal Imaging

KW - Positron-Emission Tomography

KW - Tomography, X-Ray Computed

U2 - 10.1586/14737140.2014.883280

DO - 10.1586/14737140.2014.883280

M3 - Journal article

C2 - 24702537

SN - 1473-7140

VL - 14

SP - 595

EP - 620

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 5

ER -

PET/CT in therapy evaluation of patients with lung cancer

Abstract

Emneord

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater